zoledronic acid 5mg100ml solution for infusion vials
sun pharmaceutical industries europe b.v. - zoledronic acid monohydrate - solution for infusion - 50microgram/1ml
atosiban 37.5mg5ml concentrate for solution for infusion vials
sun pharmaceutical industries europe b.v. - atosiban acetate - solution for infusion - 7.5mg/1ml
atosiban 6.75mg0.9ml solution for injection vials
sun pharmaceutical industries europe b.v. - atosiban acetate - solution for injection - 7.5mg/1ml
sumatriptan 6mg0.5ml solution for injection pre-filled pen
sun pharmaceutical industries europe b.v. - sumatriptan succinate - solution for injection - 12mg/1ml
riluzole 50mg tablets
sun pharmaceutical industries europe b.v. - riluzole - tablet - 50mg
tobramycin 300mg5ml nebuliser liquid ampoules
sun pharmaceutical industries europe b.v. - tobramycin - nebuliser liquid - 60mg/1ml
ceziboe 0.25 mg solution for injection in pre-filled syringe
sun pharmaceutical industries europe b.v. - cetrorelix - solution for injection in pre-filled syringe - 0.25 milligram(s) - cetrorelix
amoxicillin sun 750 mg dispersible tablets
sun pharmaceutical industries europe b.v. polarisavenue 87, 2132, jh hoofdorp, netherlands - amoxicillin trihydrate - dispersible tablet - amoxicillin trihydrate 750 mg - antibacterials for systemic use
warfarin teva 0.5mg tablets
sun pharmaceutical industries europe b.v. - warfarin sodium clathrate - tablet - 0.5 milligram(s) - vitamin k antagonists; warfarin - antithrombotic agent (vitamin k antagonist) - it is indicated for the prophylaxis of venous thrombosis and pulmonary embolism, and for use in the treatment of these conditions to prevent their extensiona and for the prophylaxis of systemic embolisation in patients with rheumatic heart disease and atrial fibrillation.
warfarin teva 1 mg tablets
sun pharmaceutical industries europe b.v. - warfarin sodium clathrate - tablet - 1 milligram(s) - vitamin k antagonists; warfarin - antithrombotic agent (vitamin k antagonist) - it is indicated for the prophylaxis of venous thrombosis and pulmonary embolism, and for use in the treatment of these conditions to prevent their extension and for the prophylaxis of systemic embolisation in patients with rheumatic heart disease and atrial fibrillation.